NFATC2 and COVID-19: Compared with vehicle, VT-109 also reduced NFATC2 nuclear accumulation in endothelial and immune cells at 7 dpi (Fig. 7h, i), suggesting that VT-109 has the potential to alleviate inflammation in COVID-19-induced pneumonia.